The University of Southern Mississippi

The Aquila Digital Community
Faculty Publications
10-1-2021

Enhanced Detection of Desmoplasia By Targeted Delivery of Iron
Oxide Nanoparticles To the Tumour-Specific Extracellular Matrix
Meenu Chopra
The University of Western Australia

Jiansha Wu
The University of Western Australia

Yen Ling Yeow
The University of Western Australia

Louise Winteringham
The University of Western Australia

Tristan D. Clemons
The University of Western Australia, Tristan.Clemons@usm.edu

See next page for additional authors

Follow this and additional works at: https://aquila.usm.edu/fac_pubs
Part of the Pharmacology, Toxicology and Environmental Health Commons

Recommended Citation
Chopra, M., Wu, J., Yeow, Y., Winteringham, L., Clemons, T., Saunders, M., Kotamraju, V., Ganss, R., Feindel,
K., Hamzah, J. (2021). Enhanced Detection of Desmoplasia By Targeted Delivery of Iron Oxide
Nanoparticles To the Tumour-Specific Extracellular Matrix. Pharmaceutics, 13(10).
Available at: https://aquila.usm.edu/fac_pubs/19454

This Article is brought to you for free and open access by The Aquila Digital Community. It has been accepted for
inclusion in Faculty Publications by an authorized administrator of The Aquila Digital Community. For more
information, please contact Joshua.Cromwell@usm.edu.

Authors
Meenu Chopra, Jiansha Wu, Yen Ling Yeow, Louise Winteringham, Tristan D. Clemons, Martin Saunders,
Venkata Ramana Kotamraju, Ruth Ganss, Kirk W. Feindel, and Juliana Hamzah

This article is available at The Aquila Digital Community: https://aquila.usm.edu/fac_pubs/19454

pharmaceutics
Article

Enhanced Detection of Desmoplasia by Targeted Delivery of
Iron Oxide Nanoparticles to the Tumour-Specific
Extracellular Matrix
Meenu Chopra 1,† , Jiansha Wu 1,† , Yen Ling Yeow 1 , Louise Winteringham 1 , Tristan D. Clemons 2,3 ,
Martin Saunders 4 , Venkata Ramana Kotamraju 5 , Ruth Ganss 1 , Kirk W. Feindel 4 and Juliana Hamzah 1,6, *
1

2

3
4

5

6



Citation: Chopra, M.; Wu, J.; Yeow,
Y.L.; Winteringham, L.; Clemons, T.D.;
Saunders, M.; Kotamraju, V.R.; Ganss,
R.; Feindel, K.W.; Hamzah, J.
Enhanced Detection of Desmoplasia
by Targeted Delivery of Iron Oxide
Nanoparticles to the Tumour-Specific
Extracellular Matrix. Pharmaceutics
2021, 13, 1663. https://doi.org/
10.3390/pharmaceutics13101663
Academic Editor: Ki Young Choi
Received: 3 September 2021
Accepted: 30 September 2021
Published: 12 October 2021

Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in

*
†

Harry Perkins Institute of Medical Research, Centre for Medical Research, QEII Medical Centre,
The University of Western Australia, Perth 6009, Australia; 21936806@student.uwa.edu.au (M.C.);
susan.wu@perkins.org.au (J.W.); yen.yeow@perkins.org.au (Y.L.Y.);
louise.winteringham@perkins.org.au (L.W.); ganss@perkins.org.au (R.G.)
School of Molecular Sciences, The University of Western Australia, Perth 6009, Australia;
Tristan.Clemons@usm.edu
School of Polymer Science and Engineering, University of Southern Mississippi, Hattiesburg, MS 39406, USA
Centre for Microscopy, Characterisation and Analysis, The University of Western Australia,
Perth 6009, Australia; martin.saunders@uwa.edu.au (M.S.); Kwfeinde@dal.ca (K.W.F.)
Cancer Research Center, Sanford Burnham Prebys Medical Discovery Institute, San Diego, CA 92037, USA;
vraman@califiapharma.com
Curtin Health Innovation Research Institute, Curtin University, Perth 6102, Australia
Correspondence: juliana.hamzah@perkins.org.au; Tel.: +61-861510732
These authors contribute equally to this work.

Abstract: Diagnostic imaging of aggressive cancer with a high stroma content may benefit from
the use of imaging contrast agents targeted with peptides that have high binding affinity to the
extracellular matrix (ECM). In this study, we report the use of superparamagnetic iron-oxide nanoparticles (IO-NP) conjugated to a nonapeptide, CSGRRSSKC (CSG), which specifically binds to the
laminin-nidogen-1 complex in tumours. We show that CSG-IO-NP accumulate in tumours, predominantly in the tumour ECM, following intravenous injection into a murine model of pancreatic
neuroendocrine tumour (PNET). In contrast, a control untargeted IO-NP consistently show poor
tumour uptake, and IO-NP conjugated to a pentapeptide, CREKA that bind fibrin clots in blood
vessels show restricted uptake in the angiogenic vessels of the tumours. CSG-IO-NP show three-fold
higher intratumoral accumulation compared to CREKA-IO-NP. Magnetic resonance imaging (MRI)
T2 -weighted scans and T2 relaxation times indicate significant uptake of CSG-IO-NP irrespective of
tumour size, whereas the uptake of CREKA-IO-NP is only consistent in small tumours of less than
3 mm in diameter. Larger tumours with significantly reduced tumour blood vessels show a lack of
CREKA-IO-NP uptake. Our data suggest CSG-IO-NP are particularly useful for detecting stroma in
early and advanced solid tumours.
Keywords: tumour targeting; extracellular matrix; CSG; nanoparticles; magnetic resonance imaging

published maps and institutional affiliations.

1. Introduction
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Clinical imaging techniques including magnetic resonance imaging (MRI), computed
tomography (CT) and ultrasound can detect sporadically growing solid tumours, but their
sensitivity and specificity decrease when detecting early-stage and metastatic diseases [1–3].
Moreover, the lack of sensitivity in both imaging-guided intraoperative visual inspection
and manual palpation performed by the surgeon may result in incomplete resection of
the tumour [4,5]. Hence, more sensitive and accurate detection strategies are needed for
effective tumour removal and treatment. Furthermore, solid tumours typically display
profound inter- and intratumoral molecular and phenotypic heterogeneity, not only in the
cancerous cells, but also in the stromal cell and non-cell compartments [6,7]. Acquiring
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tumour biopsies prior to treatment is challenging as the procedure is invasive, takes
longer to process and interpret and, consequently, is more expensive and not without
risk to the patient [8]. Therefore, to improve the treatment outcome, it is important to
improve diagnostic accuracy of tumour heterogeneity; molecular imaging is emerging as
an important tool to achieve this. Importantly, this knowledge could inform the design of
effective treatment strategies including patient stratification for better treatment options,
monitoring therapeutic resistance and identifying metastatic disease.
Current systemic therapy and delivery of imaging agents to tumours rely mainly
on the enhanced permeability and retention (EPR) effect of leaky tumour vasculature
to deliver anti-cancer or imaging agents [9]. In diagnostic imaging, nanoparticle-based
contrast agents, which have been traditionally exploited for cancer detection, have some
limitations [10,11]. For example, iron oxide nanoparticles (IO-NP), including particles
marketed as Feridex® and Resovist® , failed commercially as contrast agents for solid
tumours [12]. Their performance is poor partly because IO-NP do not penetrate sufficiently
into solid tumours, and are taken up non-specifically in healthy surrounding tissue and
rapidly cleared by the kidney or phagocytosed by the reticuloendothelial system in the
liver and spleen [10–12].
To improve intratumoral delivery in solid tumours, imaging payloads including
nanoparticle-based contrast agents can be actively targeted to bind to specific compartments
in tumours using molecular ligands [13,14]. Widely used ligands include peptides that
have high binding specificity to molecules aberrantly expressed in tumour blood vessels,
hypoxic cells or immune cell infiltrates. Since the discovery of cell-adhesion molecules that
are aberrantly expressed in tumours, which can be targeted by the RGD peptide [15,16],
other tumour-targeting peptides have been discovered and used as effective ligands for
systemic delivery of various drug and imaging payloads [17–25]. When directly coupled
onto drugs or multivalently conjugated onto nanoparticles, tumour-targeting peptides can
significantly enhance the intratumoral delivery of payloads, advancing their diagnostic
and therapeutic use in multiple tumour types [23,26–33].
Solid tumours that are highly angiogenic can be effectively targeted with vessel homing peptides. For example, the RGD peptide specifically recognises αv β3 and αv β5 integrins
on tumour endothelia [15], the NGR peptide selectively binds CD13 molecule in tumours
but not in other CD13-expressing tissues [20] and the CREKA peptide binds to fibrin-clotted
proteins commonly found in sprouting tumour blood vessels [23]. These vessel-targeting
peptides have been extensively used to deliver radiotracers and nanoparticle-based contrast agents for multiple imaging modalities including MRI, ultrasound, CT and positron
emission tomography (PET) [34–38]. However, the vessel network in solid tumours is
highly heterogeneous in its distribution and function [39]. Tumours with fewer or less
perfused blood vessels are harder to diagnose and they are likely to be less sensitive to vesseltargeted agents. Thus, alternative molecular targets for more effective delivery of imaging
and therapeutic agents to enhance diagnostic and therapeutic strategies are needed.
The hallmarks of solid tumours associated with aggressive malignancies, poor prognosis and resistance to drug delivery include dense stroma with excessive production
of ECM [40]. In treatment-resistant pancreatic adenocarcinoma and breast cancers, the
fibrotic stroma and ECM may comprise 60–90% of the tumour mass [41–43]. The ECM
in these tumours is made of highly abundant scaffolds of fibrillar proteins, glycoproteins
and glycosaminoglycans, which are topographically and structurally different to the ECM
of surrounding normal tissue [44]. The high ECM content can restrict tumour uptake
of imaging agents and anti-cancer therapeutics [45]. In addition, desmoplastic cancers
are more resistant to immunotherapy [46]; high ECM density hampers the migration of
anti-tumour immune cells from reaching and interacting with the tumour cells [47] and
downregulates the cytotoxic activity of anti-tumour T cells [48]. The abundant and aberrant
tumour ECM has yet to be fully exploited by imaging technology as a means to diagnose
cancer and evaluate novel therapies.
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We have recently reported the discovery of a peptide, CSG (CSGRRSSKC) that binds
specifically to the laminin-nidogen-1 complex of the ECM in mouse and human breast,
pancreas and liver tumours [49]. We have shown that CSG fused to a cytokine, TNFα,
acts as a delivery agent allowing for specific binding of TNFα to tumour ECM, triggering
effective immune-mediated anti-tumour effects [49].
In this study, we use CSG to deliver IO-NP to the ECM compartment of solid tumours.
Using a murine PNET model that spontaneously develops angiogenic tumour nodules
with significant ECM content, we compare the intratumoral uptake of CSG-targeted IO-NP
to control untargeted and CREKA-targeted IO-NP.
2. Materials and Methods
2.1. Peptide
CSG is a 9-amino acid cyclic peptide (CSGRRSKC), referred to as CSG, based on its
first three amino acids, and CREKA is a linear pentapeptide (Cys-Arg-Glu-Lys-Ala). Briefly,
peptides, amidated at the C-terminus, were synthesised on a microwave-assisted automated peptide synthesiser (Liberty; CEM, Matthews, NC, USA) following Fmoc/tertiary
butyl strategy on rink amide MBHA resin with HBTU (N,N,N 0 ,N 0 -tetramethyl-O-(1Hbenzotriazol-1-yl) uronium hexafluorophosphate) activator (or O-(benzotriazol-1-yl)-N,N,
N 0 ,N 0 -tetramethyluronium hexafluorophosphate), collidine activator base and 5% piperazine for deprotection. Fluorescein was incorporated during the synthesis at the N-terminus
of the sequence as 5(6)-carboxyfluorescein, with a spacer, 6-aminohexanoic acid, separating
the fluorophore and the sequence. All the peptides were purified to purities >90% by HPLC
with acetonitrile and water gradient mixtures with 0.1% TFA. Peptides were analysed by
MALDI and found to have [M+H] 1554.75 for FAM-cys-CSG, and 1076.24 for FAM-CREKA.
2.2. PNET Mouse Model
RIP1-Tag5 mice (on a C3H background, provided by D. Hanahan) express the oncogene SV40 Large T antigen (Tag) under the control of the rat insulin gene promoter (RIP) in
pancreatic β cells, and develop spontaneous insulinoma as previously described [50]. The
experimental protocol was approved by the Animal Ethics Committee of the University of
Western Australia (UWA). RIP1-Tag5 mice at ≈29–30 weeks of age were used in the studies,
as they are known to develop advanced-stage tumour nodules. The mice were kept under
pathogen-free conditions. A minimum of n = 3 mice per group were used in each study.
2.3. In Vivo Peptide Binding
Tumour-bearing mice were injected intravenously (tail vein) with 100 µL of either
1 mM FAM-CSG or FAM-CREKA in phosphate saline buffer (PBS). After 1 h, animals were
euthanised and perfused by transcardial perfusion with sterile PBS to remove the unbound
peptide. Tumours were excised, embedded in O.C.T. (Tissue-Tek® ) as frozen (unfixed) and
stored at 80 ◦ C for histology analysis.
2.4. Synthesis of Targeted Iron Oxide Nanoparticles
Superparamagnetic iron oxide nanoparticles (IO-NP) were prepared as per previously
established protocols [51] with slight modification. Briefly, the homogenous IO-NP was
made by a co-precipitation method in an aqueous solution with a molar ratio of Fe (II)
to Fe (III) = 0.5 and pH ≈ 11–12. In brief, 5.2 g of FeCl3 and 2.0 g of FeCl2 were dissolved in the aqueous solution and added dropwise into 250 mL of 1.5 M NaOH solution
under vigorous stirring. The resulting solution was heated at 70 ◦ C for 2 h. A black
precipitate was generated, purified deoxygenated water was added and the solution was
centrifuged at 4000 rpm. The resulting nanoparticles were anionic, the anionic charge of the
nanoparticles was neutralised by adding 500 mL of 0.01M HCI solution to the precipitate
(with stirring) [51]. The colloidal nanoparticles were again separated by centrifugation
(4000 rpm). The bare IO-NP were then non-covalently coated with a thin layer of dextran (MW 5220, Sigma, Australia) as previously described [52]. Fluorescein-peptide-lipid
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labelling was prepared by coupling 1,2-distearoyl-sn-glycerol-3-phosphoethanolamine-Nmaleimide (DSPE-PEG2000-maleimide, Avanti Polar Lipids) with peptide carboxyfluorescein (FAM) bearing a cysteine on its N-terminus in 1:1 molar ratio. The dextran-coated
IO-NP were encapsulated in PEGylated lipids by combining the dextran-coated IO-NP
with DSPE-PEG2000 and DSPE-PEG-maleimide-2000-FAM-peptide (in chloroform) in
1:1:0.37 molar ratios [24,53]. The iron concentration was determined by a standard curve
prepared from the stock solution (FeSO4 , 40 mg/L). The stock solution at different concentrations (0.5–5 mg/mL) was dissolved in acid (0.2% hydroxylamine hydrochloride) and
sodium citrate was added to maintain an acidic pH for Fe, forming the phenanthroline/
Fe2 complex. The quantification of the known dilution was done spectrophotometrically
by adding o-Phenanthroline (0.0075% w/v) into each solution [54].
2.5. Material Characterisation
Particle size, morphology, crystallinity and size distribution were obtained using
high-resolution transmission electron microscopy (HR-TEM) and selected area electron
diffraction (SAED) carried out on a FEI Titan G2 80-200 TEM at an accelerating voltage of
200 kV. To determine bare IO-NP size and morphology, a drop of IO-NP solution was placed
on the surface of a carbon-coated copper grid and dried at room temperature overnight
before imaging using HR-TEM. The average hydrodynamic size and zeta potential of
all IO-NP were characterised using dynamic light scattering (DLS, Nano ZS90; Malvern
Instruments, Malvern, UK), using a 4 mW He-Ne laser operating at 633 nm with a scattering
angle of 173◦ . Measurements were taken in triplicate after an initial equilibration period of
2 min. For calibration, the measurement’s ‘material’ was defined as nanoparticles (refractive
index of 1.515 and absorbance of 0.05) and ‘dispersant’ was defined as water at 25 ◦ C
(refractive index of 1.330 and viscosity of 0.887). The volume-weighted hydrodynamic
radius and zeta potential of CSG-IO-NP, CREKA-IO-NP and untargeted-IO-NP were
presented as mean ± standard deviation.
2.6. In Vitro IO-NP MRI
MRI scans were performed at 9.4 T with a Bruker BioSpec 94/30 magnet, Avance III HD
console and ParaVision 6.0.1 acquisition software. To determine the transverse relaxation time
(T2) of IO-NP, IO-NP (after encapsulation in PEG) were prepared at different concentrations
of Fe (0.02, 0.05, 0.07, 0.18 and 0.36 mM of Fe) in PBS. The T2 data were collected using a 2D
multi-slice multi-echo (MSME) sequence with the following parameters: echo time (TE) = 1.5 ms,
repetition time (TR) = 2000 ms, slice thickness = 0.5 mm, pixel size = 100 µm × 100 µm, number of
echoes = 64, 4 averages and total experiment time = 16 min. Bruker ParaVision and ImageJ
software were used for MR image reconstruction and analysis.
2.7. Ex Vivo Tissue MRI
A 100 µL bolus of CSG-IO-NP, CREKA-IO-NP and untargeted IO-NP (5 mg/kg Fe)
were injected intravenously (tail vein) into the RIP1-Tag5 mice. After 4 h circulation, mice
were perfused with sterile PBS; then, tissues were collected and fixed in 2% formalin for
2 h and embedded in 2% agarose. Following the MRI localizer scan, a series of three scans
were completed with 23 interleaved coronal slices: (1) a T2*-weighted image (FLASH: echo
time (TE) = 10 ms; repetition time (TR) = 600 ms; flip angle (FA) = 30◦ ; averages (NA) = 2;
acquisition time (TA) = 3 min); (2) T2* map (multi-gradient echo (MGE): TR = 1250 ms;
TE = 2.6 ms; FA = 90◦ ; number of echoes (NE) = 10; echo spacing (ESP) = 5 ms; TE (effective)
= 2.6 to 47.6 ms; and TA = 5 min); and (3) a T2 map (MSME: TR = 3150 ms; TE = 8 ms;
FA = 90◦ ; refocusing pulse = 180◦ ; NE = 16; ESP = 8 ms; TA = 7 min 53 s). For the above
scans, the field of view (FOV) = 3.6 × 3.6 cm2 , matrix (MTX) = 240 × 240, slice thickness
(ST) = 0.5 mm and slice gap = 25 µm. T2* and T2 parameter maps were calculated from
the MGE and MSME datasets, respectively, using the ParaVision 6.0.1 macro fitinlsa, which
fits the signal for each pixel according to a mono-exponential decay. Image analysis was
performed using ImageJ. Tumour volume and IO-NP-induced changes in MRI signal level
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were measured by using the Image Display and Processing Tool. ROIs for each tumour was
manually defined using the track tool, based on the MSME image with TE = 8 ms. Statistics
for tumour volumes were obtained by combining the ROI statistics on an image slice by
slice basis.
2.8. In Vivo Lectin Perfusion
For lectin perfusion, the mice were i.v. injected with 100 µg of FITC-labelled tomato lectin
(Lycopersicon esculentum; Vector). After 10 min of circulation, mice were heart-perfused with
2% neutral-buffered formalin (w/v) and tumours were frozen in the O.C.T. compound.
2.9. Immunofluorescence and Immunohistochemistry Analysis
Tumours collected for peptide and IO-NP binding and post-MRI were analysed.
Tissue distribution of fluorescein (FAM)-labelled CSG, FAM-CREKA, FAM-IO-NP, FAMCSG-IO-NP or FAM-CREKA-IO-NP were detected on 8 µm tissue cross-sections based on
their fluorescence intensity and reactivity to anti-fluorescein-HRP antibody (polyclonal,
GeneTex) and counter-stained with haematoxylin or methyl green (Vector Laboratories,
Burlingame, CA, USA). For co-staining analysis, the following antibodies were used: antiCD31 (390; ebioscience), anti-laminin (polyclonal; Millipore) and anti-collagen I (polyclonal;
Abcam). For secondary detection, fluorescence-labelled, 594-conjugated anti-rat, rabbit or
goat IgG (LifeTechnologies, Carlsbad, CA, USA) were used. Images were captured on a
Nikon Ti-E microscope (Nikon Instrument Inc., Melville, NY, USA) or ScanScope XT (Aperio
Technology, Inc., Vista, CA, USA). Image analysis and quantification were performed either using
NIS software modules (version 4.0) or ImageScope version 12.1.0.5029 (Aperio Technology, Inc.,
Vista, CA, USA).
2.10. Statistical Analysis
A minimum of 3 mice per group was used in all studies. For histological quantification,
raw data were obtained from each microscopically identified tumour on tissue section
(1–3 identified tumours/tissue sections). Raw data were obtained from at least three
fields of view for tumours >3 mm or from the entire tumour section for tumours <3 mm.
Statistical analyses were performed using GraphPad Prism 7 (GraphPad Prism Software,
San Diego, CA, USA). Data were analysed by the Student’s t-test (two-tailed) or one-way
analysis of variance (ANOVA). A p value < 0.05 was considered statistically significant.
Error bars indicate SEM. Experiments were carried out in an unblinded fashion.
3. Results
3.1. CSG and CREKA Have Distinct Binding Targets in PNET In Vivo
We first compare the in vivo CSG and CREKA binding to RIP1-Tag5 tumours following an i.v. injection of each FAM-labelled peptide. Figure 1 compares the peptide
intratumoral distribution, which matches our previous in vitro binding assessment [49].
Following i.v. injection, both peptides accumulate intratumorally. CREKA accumulation is
specifically confined to the CD31-positive tumour blood vessels (Figure 1A). In contrast,
CSG accumulates mostly in areas that are outside of CD31-positive tumour blood vessels
(Figure 1B), where it colocalises with tumour laminin (Figure 1C). These in vivo binding
data confirm different binding targets for CSG and CREKA in PNET, which we seek to
exploit for targeted delivery of IO-NP. Previous studies have shown that CSG and CREKA
have limited binding in normal healthy tissues [23,49].
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Figure 1. CSG and CREKA specifically recognise different compartments in RIP1-Tag5 tumours.
Tumour-bearing RIP1-Tag5 mice were i.v. injected with 0.1 µmol of FAM-CREKA or FAM-CSG,
Figure 1. CSG and CREKA specifically recognise different compartments in RIP1-Tag5 tumours. Tumour-bearing RIP1and tissues
werewith
collected
after
1 h of circulation.
(A–D) show
distribution
of FAM-CREKA
Tag5 mice were
i.v. injected
0.1 µmol
of FAM-CREKA
or FAM-CSG,
and tissues
were collected
after 1 h ofand
circulation.
FAM-CSG
(green)
in
tumours
co-stained
either
with
the
vascular
marker
CD31
or
the
ECM
marker marker
(A,B,C,D) show distribution of FAM-CREKA and FAM-CSG (green) in tumours co-stained either with
the vascular
laminin
(red). Scale
bars:
50 µm.
CD31 or the
ECM marker
laminin
(red).
Scale bars: 50 µm.

3.2. Synthesis and Characterization of IO-NP
The IO-NP synthesised in this study were first characterised in terms of size, shape
and composition (Figure 2). Structural characterisation of bare IO-NP was performed using
high-resolution transmission electron microscopy (HR-TEM) and selected area electron
diffraction (SAED). The size and morphology of bare IO-NP, as shown in Figure 2A, are
uniformly spherical and ≈10 nm in diameter. The lattice fringe spacings evident from
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urement of the lattice spacings was consistent with the atomic spacings anticipated for
magnetite, Fe3O4_ IO-NPs (Table 1) [55].
As illustrated in Figure 3, our imaging agents consist of three main elements—(i)
dextran-coated IO, encapsulated by (ii) PEGylated lipids and (iii) PEGylated lipids—
which were tagged with either FAM-labelling (untargeted), FAM-CREKA or FAM-CSG
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Figure 2. Structural and morphological characterisation of IO-NPs. (A) High-resolution transmission electron microscopy
(HR-TEM)
micrographs
of IO-NPs and characterisation
(B) a magnified view
of a single
NP. (C) Selectedtransmission
area electronelectron
diffraction
(SAED)
Figure 2. Structural
and morphological
of IO-NPs.
(A) High-resolution
microscopy
pattern
acquired
from anofIO-NP
assembly.
(HR-TEM)
micrographs
IO-NPs
and (B) a magnified view of a single NP. (C) Selected area electron diffraction (SAED)
pattern acquired from an IO-NP assembly.
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diffraction
(SAED) lattice
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As illustrated in Figure 3, our imaging agents consist of three main elements—
(i) dextran-coated IO, encapsulated by (ii) PEGylated lipids and (iii) PEGylated lipids—
which were tagged with either FAM-labelling (untargeted), FAM-CREKA or FAM-CSG via
cysteine-maleimide conjugation. The final hydrodynamic size of the untargeted IO-NP,
CREKA-IO-NP and CSG-IO-NP are between 28 and 35 nm, and all IO-NP have a positive
8 of 17
surface charge after conjugation, as measured by DLS (Table 2). The indicated morphological characteristics, superparamagnetic core, hydrodynamic sizes of less than 200 nm and
positive overall surface charges of our synthesised IO-NPs are comparable to the previously
reported MRI contrast agents suitable for biomedical and in vivo applications [56,57].

Figure 3. Schematic illustration of IO-NP consisting of a dextran-coated IO particle (core, gray) encapsulated by DSPE-PEG2000
lipids (in red) with the lipids tagged to a peptide or cysteine residue (in green). FAM-X- Cys-CSG (CSGRRSSKC), FAM-X-CREKA
or FAM-X-Cys
(untargeted)
is tagged
to the consisting
lipids via cysteine-maleimide
(Mal)
interaction
(shown
the box).
Figure
3. Schematic
illustration
of IO-NP
of a dextran-coated
IO particle
(core,
gray)inencapsulated
by DSPEPEG2000 lipids (in red) with the lipids tagged to a peptide or cysteine residue (in green). FAM-X- Cys-CSG (CSGRRSSKC),
FAM-X-CREKA or FAM-X-Cys (untargeted) is tagged to the lipids via cysteine-maleimide (Mal) interaction (shown in the
box).

Table 2. IO-NP sizes and their zeta potentials as measured by dynamic light scattering (DLS).
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Table 2. IO-NP sizes and their zeta potentials as measured by dynamic light scattering (DLS).
NPs

Size (nm)

Zeta Potentials (mv)

Untargeted FAM-IO NP

28.31 ± 4.77

32.20 ± 2.26

FAM-CREKA-IO-NP

35.40 ± 8.10

38.43 ± 7.10

FAM-CSG-IO-NP

33.83 ± 5.57

34.88 ± 4.83

3.3. Enhanced Intratumoral ECM Binding of CSG-IO-NP Compared to Untargeted IO-NP
and CREKA-IO-NP

Pharmaceutics 2021, 13, x

We compare the intratumoral distribution and levels of CSG-IO-NP to the untargetedIO-NP and CREKA-IO-NP, following 4 h of in vivo circulation (Figure 4). Particle distribution was confirmed by histological detection using an antibody against the fluorescein label
(Figure 4). The untargeted IO-NP show limited intratumoral tumour accumulation. Both
CREKA-IO-NP and CSG-IO-NP show specific intratumoral accumulation and minimal
binding to exocrine tissue surrounding the tumours (Figure 4A). The accumulation of
CSG-IO-NP in tumours is at least three-fold higher than in the CREKA-IO-NP tumour
binding. (Figure 4B). CREKA-IO-NP binding in tumours correlates with the location of
CD31-positive endothelia (Figure 5A), whereas CSG-IO-NP binding correlates mainly
with tumour ECM detected with collagen I, laminin and nidogen-1 staining (Figure 5B).
9 of 17
The finding is consistent with the intratumoral distribution of CREKA and CSG as free
peptides (Figure 1), suggesting that both CSG and CREKA specifically deliver IO-NP to
their respective target.

Figure 4. Cont.
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3.4. CSG-IO-NP Is an Effective MRI Contrast Agent, Irrespective of Tumour Sizes
3.4. CSG-IO-NP Is an Effective MRI Contrast Agent, Irrespective of Tumour Sizes
To assess the use of IO-NP as an effective MRI contrast agent, we first evaluated
To assess the use of IO-NP as an effective MRI contrast agent, we first evaluated T2*T2*-weighted and T2 relaxation MR images for a range of concentration of IO-NP from 0.02
weighted and T2 relaxation MR images for a range of concentration of IO-NP from 0.02 to
to 0.36 mM Fe in vitro. Figure 6A demonstrates the effect of different iron concentrations
0.36 mM Fe in vitro. Figure 6A demonstrates the effect of different iron concentrations on
on T2, consistent with previous reports [53,56].
T2, consistent with previous reports [53,56].
We then performed ex vivo MRI scans of RIP1-Tag5 tumours with exocrine pancreatic tissue following the 4 h in vivo circulation of CSG-IO-NP, CREKA-IO-NP and untargeted IO-NP in tumour-bearing mice. Figure 6C–E show T2* and T2 relaxation images of
scanned tumours based on their small (diameter < 3 mm) and large (diameter > 3 mm)
sizes. Based on changes in the T2 relaxation time that indicate the relative amount of IONP
in tumours, our data (Figure 6F) show significant CSG-IO-NP intratumoral accumulation
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We then performed ex vivo MRI scans of RIP1-Tag5 tumours with exocrine pancreatic
tissue following the 4 h in vivo circulation of CSG-IO-NP, CREKA-IO-NP and untargeted
IO-NP in tumour-bearing mice. Figure 6C–E show T2* and T2 relaxation images of scanned
tumours based on their small (diameter < 3 mm) and large (diameter > 3 mm) sizes. Based
on changes in the T2 relaxation time that indicate the relative amount of IONP in tumours,
our data (Figure 6F) show significant CSG-IO-NP intratumoral accumulation irrespective
of tumour size. CREKA-IO-NP are consistently detectable only in small tumours, and the
untargeted IO-NP show limited uptake in all tumours.
Since tumour sizes affect only CREKA-IO-NP intratumoral binding, we compared
the blood vessel and ECM composition in small and larger sized tumours. The RIP1Tag5 tumours are known for their blood vessel heterogeneity with advanced insulinoma
showing poor perfusion [50,58]. To identify ‘functional’ blood vessels, we compared
lectin-painted tumour blood vessels (following i.v. injection of FITC-labelled lectin, a
surrogate marker for tumour perfusion) [30,59] with collagen-I-positive ECM content
(Figure 7A). Our data (Figure 7B) show lectin-positive vessels are significantly reduced in
larger
in all
Pharmaceutics 2021,
13, x tumours (diameter > 3 mm), whereas there are no changes in the ECM
12 ofcontent
17
tumours irrespective of tumour sizes. This finding suggests that CSG-IO-NP may be useful
for a broader range of tumour sizes due to their ECM abundance.

Figure 7. ECM and blood vessel contents in tumours correlate with the effectiveness of CSG and
+
CREKA
to deliver
IO-NP.
(A) Lectin
(green) inoftumours
after toRIP1-Tag5
Figure 7. ECM
and blood
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CSG and CREKA
deliver IO- mice received
+ vessels (green) in tumours after RIP1-Tag5 mice received an i.v. injection of FITC-labelled lectin (0.1 µmol).
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Top:
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ameter > 3 mm). Bottom: The same micrographs indicating lectin+ area and collagen I expression (red). Scale bars: 100 µm.
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(B) Quantification
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The same
micrographs
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(B) Quantification of % lectin+ /tumour (left), % collagen-I+ expression/tumour (middle) and ratio of

lectin:collagen-I (right) with mean ± SEM are shown (10 tumours from n = 3 RIP1-Tag5 mice (*** p < 0.001
for Student’s t-test).
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4. Discussion
Using the CSG peptide to target aberrant ECM in solid tumours, we developed a
targeted IO-NP for effective intratumoral delivery. Our CSG-IO-NP are particularly useful
as an MRI contrast agent to mark tumours based on their content of desmoplastic stroma.
In PNET tumours that are intratumorally resistant to the untargeted IO-NP, we found
CSG-IO-NP substantially overcome the EPR limitation. Their intratumoral accumulation
and binding to ECM, at least in the RIP1-Tag5 tumours, are not limited by changes in
tumour size or tumour blood vessel content.
Solid tumours often develop resistance to systemic delivery [45,60]. Hence, nanoparticlebased imaging agents have been commonly used to detect tumour nodules based on
contrast enhancement generated by their accumulation in the normal and marginal tissues
and lack of uptake in tumours. For example, in a liver cancer model, surface-enhanced
Raman scattering (SERS) nanoparticles were used based on their efficient homing to
healthy liver tissue but not to intrahepatic malignancies [61]. Similarly, the pre-clinical
and clinical use of MRI- and PET-based contrast agents is often based on their contrast
enhancement that allows for the delineation of small peritumoral vessels surrounding the
tumour and tumour rim [60–62]. In this study, we used the RIP1-Tag5 tumours for imaging
assessment because these tumours, while highly angiogenic, are poorly perfused and
largely impenetrable to drugs and imaging agents [49,58]. The imaging contrast generated
by MRI scans shows traces of untargeted IO-NP only around the marginal tissue and not
in the tumour parenchyma (Figure 6), confirming the intratumoral barrier that forms in
solid tumours. These data support our previous findings [49] and imaging studies in other
experimental and clinical tumours [61,63,64].
An alternative approach for contrast enhancement is to increase the uptake of the
imaging agent in tumours and reduce the non-specific binding in the surrounding tissue.
This is achieved through the use of imaging agents that effectively bind or are reactive
to the expression of specific molecular characteristics that are unique to tumours and are
not present in the surrounding healthy tissues [13,14]. This approach relies on unique
specificity and abundance of the molecular targets [13,14]. In this study, we increase the
intratumoral uptake of IO-NP using the tissue homing peptides CREKA and CSG. We
show CREKA and CSG, when tagged onto IO-NP, retain their binding to tumour blood
vessel and ECM targets, respectively.
Our histology analysis and MRI scans of tumours following the i.v. injection of
CREKA-IO-NP and CSG-IO-NP provide functional and molecular information on the
state of the tumour microenvironment at early and advanced stages. CREKA binding
to the fibrin-clotted protein that localises within angiogenic vessels has been widely
used to target drugs and nanoparticles to tumour blood vessels for theragnostic purposes [23,27,31,32,36,38]. Similarly, in RIP1-Tag5 tumours, CREKA-IO-NP localise within
blood vessels in relation to vessel numbers and functionality. Reduced intratumoral uptake
of CREKA-IO-NP correlates with a lower number of lectin-painted blood vessels in larger
RIP1-Tag5 tumours, indicating that poorly perfused blood vessels in larger size tumours
are less receptive to CREKA targeting. This finding suggests heterogeneity of blood vessel
functionality at different stages may limit the use of vessel-targeted imaging agents.
Previously, we showed that the target for CSG binding, the laminin-nidogen-1 complex, is an extensive network formed throughout the RIP1-Tag5 tumours and overlaps with
fibrillar collagens including collagen-1 [49]. RIP1-Tag5 tumours express two- to three-fold
higher laminin-nidogen-1 complex than the normal exocrine pancreas. Importantly, unlike
normal tissue ECM that is expressed exclusively as a thin basement membrane supporting
vessels and epithelia, in tumours, laminin and nidogen-1 are also aberrantly expressed
as avascular ECM [49]. These findings raise the possibility that structural differences in
tumour ECM, absent in normal ECM, expose an otherwise hidden epitope for CSG binding. CSG binding is highly specific for tumour ECM and not ECM in normal tissue [49].
Analysis of IO-NP distribution in RIP1-Tag5 tumours shows CSG-IO-NP are dispersed
within tumour ECM, well away from the nearest angiogenic vessels, with the overall
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intratumoral amount of CSG-IO-NP at least double that of CREKA-IO-NP. Here, we show
the abundance of ECM in RIP1-Tag5 tumours is consistent in small and large tumours,
resulting in a reliable intratumoral accumulation of CSG-IO-NP, unlike CREKA-IO-NP,
which are dependent on tumour size and blood vessel content.
CSG-IO-NP have two important potential applications. Firstly, CSG-IO-NP may
have potential as an imaging agent for a wide range of solid tumours beyond PNET. The
laminin-nidogen-1 complex is highly conserved in mouse and human tumours and clearly
represents a robust molecular target. We have previously shown that CSG specifically
recognises ECM in murine transplant and/or transgenic breast, liver and colon cancers,
using i.v. injection or by direct in vitro binding. CSG binding is also conserved in human
pancreatic adenocarcinoma, as well as breast and hepatocellular carcinoma [49], highlighting its potential clinical use.
Secondly, we developed a new biologic agent, TNFα-CSG, which is an immunemodulating cytokine that binds specifically to tumour ECM. TNFα-CSG treatment in
preclinical cancer models effectively promotes intratumoral accumulation of cytotoxic T
cells and suppresses tumour growth without systemic toxicity or increase in metastatic
activity [49]. CSG targeting of TNFα is critical to induce vessel dilation and improve
tumour perfusion [49]. This outcome is different from the anti-vascular effect of TNFα, where
TNFα-targeted peptides bind to tumour blood vessels or ECM proteins that are primarily
located around tumour blood vessels [29,65,66]. Whilst we are interested in developing
TNFα-CSG as an anti-cancer therapeutic, as an imaging agent, CSG-IO-NP may be used for
diagnostic screening to identify patients who may benefit from TNFα-CSG therapy.
CSG targeting of TNFα and IO-NP offers complementary therapeutic and diagnostic
agents for fibrotic cancers that have aberrant laminin-nidogen-1 expression. The use of
CSG-IO-NP as a molecular imaging agent for detecting hypovascularized and fibrotic
tumours such as pancreatic ductal adenocarcinoma remains to be investigated.
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